

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: RF2/21 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 01.10.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 2														
(237) anti-streptolysin O (ASLO)					19						17	16	94%	
Samples and groups	[kU/L]													
Sample A2		195	32	16	19						17	17	100%	
(58) Beckman Coulter (AU)		189	17	8,8	6	0	CVPG	199	4,4	20%	159	239	6	
(60) Roche		218	13	5,8	6	0	CVPG	213	4,7	20%	170	256	6	
Other					7	0							5	
								3x 1, 1x 5, 2x 149, 1x 178						
Sample B2		298	41	14	19						17	16	94%	
(58) Beckman Coulter (AU)		290	22	7,6	6	0	CVPG	305	5,5	20%	244	366	6	
(60) Roche		329	9,6	2,9	6	0	CVPG	323	5,2	20%	258	388	6	
Other					7	0							5	
								3x 1, 1x 5, 2x 149, 1x 178						
st_kn_p														End of report
														Printed: 06.10.2021